MindWalk Holdings Corp.

This is an evolutionary step forward. At MindWalk, we're redefining biologics research through advanced AI, powered by our LensAI™ platform at the core. Discover how we're bringing biology to the future: youtube.com/watch?v=--o0EL… 🇺🇸 #NASDAQ: $HYFT

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗛𝗼𝗹𝗱𝗶𝗻𝗴𝘀 𝗖𝗼𝗿𝗽. 𝗥𝗲𝗽𝗼𝗿𝘁𝘀 𝗤𝟯 𝗙𝗶𝘀𝗰𝗮𝗹 𝟮𝟬𝟮𝟲 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗧𝗼𝗱𝗮𝘆 𝗮𝘁 𝟭𝟬:𝟯𝟬𝗔𝗠 𝗘𝗧 Please join us for a review of our overall results and key highlights, including: - Third Consecutive Quarter of Year-Over-Year Revenue Growth - First Annual Enterprise LensAI Platform Contract - Launch of B Cell Llama™ Nanobody Discovery Platform “This quarter, MindWalk reported its third consecutive year-over-year revenue increase and advanced three pipeline programs toward data readouts. US revenue doubled year over year, reflecting our deliberate strategic focus on North America — including the establishment of biologics services operations in the Boston and Cambridge area and ongoing commercial investment in that market. Recently, our largest enterprise AI client signed a one-year LensAI platform contract — the first of its kind for us. LensAI is actively being rolled out across our broader client base, and this is one type of contract we are scaling.” — Dr. Jennifer Bath, CEO & President, MindWalk Holdings Corp. 𝗦𝗲𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: ir.mindwalkai.com/news/news-rele… 𝗘𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗖𝗮𝗹𝗹 MindWalk will host a live conference call on March 12, 2026, at 10:30 AM ET to discuss Q3 fiscal 2026 financial results and business developments. A replay is available following the conclusion of the call. 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗖𝗮𝗹𝗹 𝗮𝗻𝗱 𝗪𝗲𝗯𝗰𝗮𝘀𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝘀 The live webcast will take place Thursday, March 12, 2026, at 10:30AM ET. The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at: ir.mindwalkai.com/events-and-pre… * 𝗪𝗲𝗯𝗰𝗮𝘀𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝘀 * Event Title: MindWalk Holdings Corp. – Third Quarter Fiscal Year 2026 Financial Results Event Date: March 12, 2026, 10:30 AM (GMT-04:00) Eastern Time (US and Canada) Attendee URL: events.q4inc.com/attendee/48688… 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁 𝗗𝗶𝗮𝗹-𝗶𝗻: USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Canada - Toronto (647) 932-3411 Canada - Toll-Free (800) 715-9871 Conference ID: 3224490 $HYFT #MindWalk #DrugDiscovery

𝗛𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗛𝗜𝗠𝗦𝗦 𝟮𝟬𝟮𝟲 (𝗠𝗮𝗿𝗰𝗵 𝟵–𝟭𝟮 | 𝗟𝗮𝘀 𝗩𝗲𝗴𝗮𝘀)? 𝗩𝗶𝘀𝗶𝘁 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗮𝘁 𝘁𝗵𝗲 𝗔𝗠𝗗 𝗯𝗼𝗼𝘁𝗵 #𝟮𝟱𝟳𝟬. With @AMD, we’re demonstrating how high-performance infrastructure is powering a new era of drug discovery. See LensAI running at production scale on AMD EPYC™ and Instinct™ — enabling faster, more efficient therapeutic development. 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗖𝗧𝗢, 𝗗𝗶𝗿𝗸 𝗩𝗮𝗻 𝗛𝗬𝗙𝗧𝗘'𝘀 𝘁𝗮𝗹𝗸 "Transforming Drug Discovery: The Power of LensAI™ + AMD EPYC™ and Instinct™" 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻: AMD Theater, Booth #2570 𝗗𝗮𝘁𝗲: Wednesday, March 11 4:30 PM PT 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗯𝗶𝗼-𝗻𝗮𝘁𝗶𝘃𝗲 𝗟𝗲𝗻𝘀𝗔𝗜. 𝗔𝗠𝗗 𝗵𝗶𝗴𝗵-𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗰𝗼𝗺𝗽𝘂𝘁𝗲. 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻-𝘀𝗰𝗮𝗹𝗲 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆. Schedule a meeting with our team at HIMSS bit.ly/47eFlR7 #HIMSS2026 #DrugDiscovery #HealthIT #DigitalHealth #MindWalk #AMD

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗶𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗶𝗻𝗴 𝗕 𝗖𝗲𝗹𝗹 𝗟𝗹𝗮𝗺𝗮™ — 𝗮 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗻𝗮𝗻𝗼𝗯𝗼𝗱𝘆 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗲𝗿𝗮 𝗼𝗳 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀, 𝗺𝘂𝗹𝘁𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, 𝗮𝗻𝗱 𝗖𝗔𝗥-𝗧 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀. VHH nanobodies solve a molecular engineering problem the industry has wrestled with for years. B Cell Llama extends our flagship B Cell Select® platform into llama-derived single-domain antibody biology, with LensAI™ available to guide each step: from target selection and immunogen design, to functional candidate triage, to in silico multispecific construct evaluation. Backed by peer-reviewed science. A study just published in ACS Biomacromolecules demonstrated modular VHH potency, cross-variant activity against targets that defeated approved therapies, and a newly described immune-priming mechanism. "What sets B Cell Llama apart is the ability to layer LensAI across the entire discovery process — triaging candidates by predicted function, and evaluating multispecific constructs in silico before a single molecule is built in the lab." — Dr. Jennifer Bath, CEO, MindWalk Holdings Corp. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁: ir.mindwalkai.com/news/news-rele… $HYFT #Nanobody #Bispecific #CART #VHH #BioNativeAI #DrugDiscovery

🗞️ INDUSTRY NEWS UPDATE: AI is playing a growing role in healthcare and life sciences, as adoption trends continue to expand across the sector. Read: aimagazine.com/news/how-and-w… 🇺🇸 #NASDAQ: $HYFT

Our LensAI™ platform, powered by our core HYFT® technology, captures and reasons over biological context to link sequences, functions, experimental outcomes, and scientific evidence into a continuously learning system with the potential to transform drug discovery. Explore: ir.mindwalkai.com/overview/defau… 🇺🇸 #NASDAQ: $HYFT

𝗠𝗮𝗿𝗸 𝘆𝗼𝘂 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿: 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗛𝗼𝗹𝗱𝗶𝗻𝗴𝘀 𝗖𝗼𝗿𝗽. 𝘁𝗼 𝗥𝗲𝗽𝗼𝗿𝘁 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗥𝗲𝗰𝗲𝗻𝘁 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗼𝗿 𝗧𝗵𝗶𝗿𝗱 𝗤𝘂𝗮𝗿𝘁𝗲𝗿 𝗙𝗶𝘀𝗰𝗮𝗹 𝗬𝗲𝗮𝗿 𝟮𝟬𝟮𝟲 𝗼𝗻 𝗠𝗮𝗿𝗰𝗵 𝟭𝟮𝘁𝗵, 𝟮𝟬𝟮𝟱 𝗮𝘁 𝟭𝟬:𝟯𝟬𝗮𝗺 𝗘𝗧. 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁 𝗗𝗶𝗮𝗹-𝗶𝗻: USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Canada - Toronto (647) 932-3411 Canada - Toll-Free (800) 715-9871 Conference ID: 3224490 𝗪𝗲𝗯𝗰𝗮𝘀𝘁 𝗔𝘁𝘁𝗲𝗻𝗱𝗲𝗲 𝗨𝗥𝗟: events.q4inc.com/attendee/48688… 𝗦𝗲𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: bit.ly/46Vdt4H $HYFT #MindWalk #TechBio

📩 NEWSLETTER SIGN-UP: Don't miss out. Our exclusive newsletter delivers the latest insights and updates on how our AI platforms are changing the game in drug discovery and development. Sign up: ir.mindwalkai.com/resources/inve… 🇺🇸 #NASDAQ: $HYFT

AI and automation are at the core of healthtech trends in 2025. We're continuing to explore AI-driven drug discovery in 2026 and beyond. See what our journey's been like: ir.mindwalkai.com/overview/defau… 🇺🇸 #NASDAQ: $HYFT

The defining feature of our platform is selectivity: the ability to distinguish toxic protein conformations from healthy ones. This plays a crucial role in mitigating development risk in neurodegenerative drug programs. Explore: ir.mindwalkai.com/news/news-rele… 🇺🇸 #NASDAQ: $HYFT

𝗢𝗻 #𝗪𝗼𝗿𝗹𝗱𝗖𝗮𝗻𝗰𝗲𝗿𝗗𝗮𝘆, 𝘄𝗲’𝗿𝗲 𝗿𝗲𝗺𝗶𝗻𝗱𝗲𝗱 𝘄𝗵𝘆 𝘁𝗵𝗶𝘀 𝘄𝗼𝗿𝗸 𝗺𝗮𝘁𝘁𝗲𝗿𝘀. Cancer affects millions of patients and families worldwide, driving an urgent need to rethink how we discover and develop new therapies. At MindWalk, our teams are advancing drug discovery by bringing together AI, data, and experimental evidence to reason across complex biological systems—working toward better options for patients across cancer types. #WorldCancerDay #CancerAwareness #DrugDiscovery #MindWalk

𝗣𝗿𝗲𝘀𝘀 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗔𝗽𝗽𝗹𝗶𝗲𝘀 𝗛𝗬𝗙𝗧® 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘁𝗼 𝗗𝗲𝘁𝗲𝗰𝘁 𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗱𝗷𝗮𝗰𝗲𝗻𝗰𝘆 𝗟𝗶𝗻𝗸𝗲𝗱 𝘁𝗼 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗥𝗶𝘀𝗸 𝗶𝗻 𝗔𝗜-𝗗𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 MindWalk announced an application of its proprietary HYFT® technology designed to identify functional adjacency - meaning different molecules can produce the same therapeutic effect even when sequence comparisons suggest they are unrelated - an emerging source of competitive, legal, and valuation risk in modern drug discovery that sequence-alignment-based analysis often fails to capture. Using HYFT® technology, MindWalk found a shared biological “signature” in influenza that stays consistent even when the virus’s genetic code changes a lot. This supports MindWalk’s approach to designing vaccine targets aimed at broader protection across strains and shows how HYFT identifies meaningful similarities in biology even when molecules do not look alike at first glance. “Functional adjacency is now one of the most under-appreciated risks in pharmaceutical R&D. If two molecules deliver the same biological effect, they may compete for the same patient, pursue similar regulatory labels, and undermine perceived differentiation even if their sequences appear unrelated. As AI accelerates protein design, teams can generate many distinct sequences that converge on the same functional outcome, increasing the likelihood of competitive overlap, IP vulnerability, and valuation compression. HYFT is intended to help identify this convergence early by evaluating similarity at the functional level, not only at the sequence level,” said Jennifer Bath, Ph.D., Chief Executive Officer of MindWalk. 𝗦𝗲𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: bit.ly/4q2qHTJ $HYFT #MindWalk #DrugDiscovery #Vaccines

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗲𝘀 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗣𝗮𝘁𝗵𝗼𝗴𝗲𝗻𝗶𝗰 𝗧𝗗𝗣-𝟰𝟯 𝗶𝗻 𝗡𝗲𝘂𝗿𝗼𝗱𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 MindWalk announced the discovery and validation of antibodies that selectively target misfolded TDP-43, a key driver in ALS, FTD, and certain Alzheimer’s cases. The work validates our ability to distinguish toxic protein states from healthy biology and reinforces MindWalk’s role as a discovery partner for complex neurodegenerative programs. 𝗦𝗲𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: bit.ly/49mFTGn 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝘀𝘁𝘂𝗱𝘆: bit.ly/4pHQMr0 Forward-looking statements apply. $HYFT #NeurodegenerativeDisease #Biologics #DrugDiscovery #MindWalk

💉 Explore the milestones that have transformed our understanding of vaccines, from their early beginnings to today’s innovations, in @salonium's full article in @WorksInProgMag. Read: worksinprogress.co/issue/the-gold… 🇺🇸 #NASDAQ: $HYFT

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝘀 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗹 𝗜𝗻𝗳𝗹𝘂𝗲𝗻𝘇𝗮 𝗣𝗿𝗼𝗴𝗿𝗮𝗺 𝘄𝗶𝘁𝗵 𝗮 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁 Validated Across Influenza A and Influenza B, Including H3N2 Subclade K and Zoonotic Influenza A Subtypes H5, H7, H9 Announcing an advance in its universal influenza program following the identification of a breakthrough functional constraint that persists across influenza viruses despite continual evolution. Using its patented HYFT® Deep Data technology, MindWalk identified a functional pattern embedded in influenza biology that remains intact beneath surface-level genetic change. 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗔𝗰𝗿𝗼𝘀𝘀 𝗜𝗻𝗳𝗹𝘂𝗲𝗻𝘇𝗮 𝗔 𝗦𝘂𝗯𝘁𝘆𝗽𝗲𝘀 𝗮𝗻𝗱 𝗜𝗻𝗳𝗹𝘂𝗲𝗻𝘇𝗮 𝗕 𝗟𝗶𝗻𝗲𝗮𝗴𝗲𝘀 Using its proprietary HYFT pattern framework, MindWalk evaluated the identified functional constraint across influenza A and influenza B datasets spanning multiple hosts. Identifying this conserved HYFT pattern across: • Influenza A in human datasets, including H3N2 and H3N2 subclade K • Influenza A in avian datasets, spanning subtypes H5, H7, and H9 • Influenza A in swine-associated datasets, including H1N1 • Influenza B across both Victoria and Yamagata lineages “Influenza constantly rewrites its genetic script, but it remains tightly constrained by the physics required for infection. Our HYFT technology allows us to identify those constraints and design directly against them,” said Jennifer Bath, Ph.D., CEO of MindWalk. 𝗦𝗲𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: ir.mindwalkai.com/news/news-rele… $HYFT #Influenza #VaccineDiscovery #Biologics #MindWalk

𝗔 𝗻𝗼𝘁𝗮𝗯𝗹𝗲 𝗺𝗼𝗺𝗲𝗻𝘁 𝗮𝘁 𝗖𝗘𝗦 𝟮𝟬𝟮𝟲 𝗗𝗿. 𝗟𝗶𝘀𝗮 𝗦𝘂, 𝗖𝗵𝗮𝗶𝗿 𝗮𝗻𝗱 𝗖𝗘𝗢 𝗼𝗳 @AMD , 𝗼𝗽𝗲𝗻𝗲𝗱 𝘁𝗵𝗲 𝘀𝗵𝗼𝘄 𝗰𝗲𝗻𝘁𝗲𝗿 𝘀𝘁𝗮𝗴𝗲 𝘄𝗶𝘁𝗵 𝗮 𝗸𝗲𝘆𝗻𝗼𝘁𝗲 𝗼𝗻 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗰𝗼𝗺𝗽𝘂𝘁𝗶𝗻𝗴. We’re grateful to work alongside partners who make progress at scale possible and to be recognized as part of that shared effort. Advancing drug discovery requires high-performance computing, alongside advanced AI, deep biological data, and discovery workflows—working together to deliver impact. Proud to be part of a moment shaping the next chapter of healthcare and scientific discovery. $HYFT #AMD #CES2026 #HealthcareInnovation #DrugDiscovery #HighPerformanceComputing

Here's how AI is already influencing the industry:

#2026 marks a new era of AI-driven #healthcare. The entire industry is changing from the ground up, and #AI is at the wheel of this progress. Explore how we’re making an impact: ir.mindwalkai.com 🇺🇸 #NASDAQ: $HYFT

📩 NEWSLETTER SIGN-UP: Be part of our journey! Get the latest updates as we evolve into a next-generation, bio-native #AI company driving innovation in #biologics #discovery and #development. Subscribe: ir.mindwalkai.com/resources/inve… 🇺🇸 #NASDAQ: $HYFT

Central to our journey in redefining the industry through #AI solutions is LensAI™, our platform engineered to make drug discovery more #efficient, #precise, and #biology-driven. Explore its potential: ir.mindwalkai.com 🇺🇸 #NASDAQ: $HYFT